Genprex, Inc. (GNPX)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 2.4500 |
| Open | 2.4850 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4300 - 2.5800 |
| 52-week range | 2.0900 - 42.4000 |
| Volume | |
| Avg. volume | 52,636 |
| Market cap | 5.352M |
| Beta (5Y monthly) | -0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
- Zacks
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
© 2024 Yahoo. All rights reserved.